Biologic Treatment Approved for Rare Blood Disorders

For the first time in nearly 14 years, the FDA has approved a treatment for adults and adolescents who have had hypereosinophilic syndrome (HES) for 6 months or longer without a known nonhematologic secondary cause.

Source: JAMA - November 3, 2020 Category: General Medicine Source Type: research